BMY stock forecast, quote, news & analysis

Key Takeaways

• BMY stock declined -5.24% over the past 30 days, falling from around $60.66 to $57.48 amid sector underperformance and profit-taking after recent highs.
• Over the past quarter, shares rose +5.9%, driven by strong Q4 2025 earnings, positive pipeline updates, and FDA approvals for key drugs like Opdivo.
• Major influences include robust growth in oncology portfolio, analyst upgrades post-earnings, but recent pressures from competitive dynamics and broader market trends.
• Upcoming Q1 2026 earnings and regulatory milestones remain key sentiment drivers.
• Dividend yield of 4.38% supports investor interest despite short-term price movement.

Bristol-Myers Squibb (BMY) Company Overview and Market Position

Bristol-Myers Squibb (BMY) is a leading global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines in oncology, hematology, immunology, cardiovascular, and neuroscience. Its core business model revolves around a diversified portfolio of blockbuster drugs like Opdivo, Eliquis, and Yervoy, alongside emerging cell therapies such as Breyanzi and Abecma. BMY holds a strong competitive position in immuno-oncology and holds significant market share against peers like Merck (MRK) and Pfizer (PFE). Solid fundamentals, including a growth portfolio contributing over 60% of revenue, explain resilience in stock price amid patent cliffs, with pipeline advancements offsetting legacy declines.

Bristol-Myers Squibb (BMY) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, BMY stock fell -5% from a closing price of $60.66 (February 20, 2026) to $57.48 (March 20, 2026), exhibiting volatile, range-bound movement after peaking near $62.89 in early March. The decline was trend-driven downward, with daily drops amid broader healthcare sector weakness.

For the quarter, shares advanced +5.9% from $54.28 (December 23, 2025) to $57.48, showing steady upward momentum punctuated by volatility, including a post-earnings rally in February before recent consolidation within the 52-week range of $42.52-$62.89.

What Drove BMY Stock Price in the Last 30 Days

The 30-day downturn reflected profit-taking after BMY hit 52-week highs near $62.89, coupled with relative underperformance versus competitors on select sessions. Despite positive developments like expanded FDA and EMA approvals for Opdivo in classical Hodgkin lymphoma, which broadened its addressable market, investor sentiment shifted amid competitive pressures in oncology. Label expansion for Sotyktu in psoriatic arthritis offered upside, but broader market trends and sector rotation weighed on the stock. Analyst sentiment remained balanced, with no major downgrades, but focus on near-term sales guidance contributed to the pullback from peaks.

What Drove BMY Stock Performance Over the Last Quarter

The quarterly gain stemmed from Q4 2025 earnings on February 5, 2026, where revenue hit $12.5 billion (up 1.3% YoY, beating estimates), led by 16% growth in the high-growth portfolio including Opdivo, Eliquis, and Breyanzi. Adjusted EPS of $1.26 exceeded forecasts, prompting upgrades from firms like Citigroup and BofA, with targets up to $68. 2026 guidance of $46-47.5 billion in revenue, despite expected declines from legacy drugs, beat lowered expectations. FDA milestones, such as Sotyktu approval and Opdivo priority reviews, alongside a Microsoft AI partnership for lung cancer detection, bolstered confidence. Institutional buying and a low beta of 0.27 provided stability amid macro rate concerns and inflation in healthcare.

Trending AI Robots

Tickeron’s Trending AI Robots page showcases the platform's top-performing AI-driven trading bots from among hundreds that analyze thousands of tickers across various markets. These curated bots employ diverse strategies, such as trend-following, mean reversion, or momentum trading, across short-term intraday to long-term horizons, with performance metrics including win rates, profit factors, and drawdowns transparently displayed. Selected based on recent profitability, consistency, and relevance to current market trends, they help traders identify opportunities in stocks like BMY. Explore the page to see real-time rankings and deploy these bots to enhance your stock analysis and trading edge.

BMY Stock Forecast Drivers: What Investors Should Watch Next

Investors should monitor Q1 2026 earnings on April 30, 2026, for updates on growth portfolio sales and 2026 guidance execution. Key pipeline readouts, including Phase 3 data for mezigdomide in multiple myeloma and protein degradation therapies, could catalyze sentiment. Regulatory progress on Opdivo combinations and Iberdomide FDA reviews remains critical. Macro factors like interest rates impacting biopharma valuations, sector demand amid aging populations, and competitive dynamics in immuno-oncology are essential. Risks include generic erosion on Eliquis and potential trial setbacks, while dividend sustainability and M&A activity warrant attention.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.